March 16, 2009

HELIX BIOPHARMA RECEIVES APPROVAL TO INITIATE PHASE II PHARMACOKINETIC CLINICAL STUDY OF TOPICAL INTERFERON ALPHA-2b IN PATIENTS WITH LOW-GRADE CERVICAL LESIONS (PDF)

(AURORA, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.